B
Bull
Bull · 25%KMDA
$7.88
情境價格
$8.290
+0.030 (+0.36%)收盤時
Loading chart…
- High
- 8.350
- Open
- 8.300
- VWAP
- 8.29
- Vol
- 55.08K
- Mkt Cap
- 289.98M
- Low
- 8.240
- Amount
- 456.80K
- EV/EBITDA, TTM
- 3.48
Kamada Ltd is Israel based company, focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.
AI analysis of Kamada Ltd (KMDA)
buyKamada Ltd is a good buy right now due to its current price of 8.29, an RSI of 63.13 suggesting bullish momentum, and a strong gross margin of 40.91% in Q2 2026. The recent FDA approval for a new laboratory enhances its competitive position, while the company's reaffirmed revenue guidance of $200 million to $205 million for 2026 indicates confidence in future growth. However, a risk to consider is the recent earnings miss, with Q1 EPS reported at 0.07, falling short of expectations by 0.05.
Analyst Ratings (1)
+68.88% upside
Buy
1 Buy
0 Hold
0 Sell
Current: 8.29
最低
13.00
平均
14.00
最高
15.00
H.C. Wainwright
Buy
$13
2025-12-09
H.C. Wainwright
2025-12-09
目標價
$13
Buy
Benchmark
Strong Buy
$15
2025-03-21
Benchmark
2025-03-21
目標價
$15
Strong Buy
HC Wainwright & Co.
Strong Buy
$11
2025-03-06
HC Wainwright & Co.
2025-03-06
目標價
$11
Strong Buy
HC Wainwright & Co.
Strong Buy
$11
2025-01-10
HC Wainwright & Co.
2025-01-10
目標價
$11
Strong Buy
HC Wainwright & Co.
Strong Buy
$11
2024-11-14
HC Wainwright & Co.
2024-11-14
目標價
$11
Strong Buy
估值指標
The current forward P/E ratio for Kamada Ltd (KMDA) is 17.06, compared to its 5-year average forward P/E of 6.17.
Alphio AI Price Scenarios for KMDA
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding KMDA
事件時間軸
資訊
8.008-17NewsfilterKamada Declares $0.17 Cash Dividend Per Share
- 5.008-12Newsfilter
Kamada CFO Chaime Orlev to Depart for New Opportunities
- 9.508-12Newsfilter
Kamada Reports Record $100.2 Million Revenue in First Half of 2026
- 7.507-20Newsfilter
Kamada Secures Plasma Supply Agreement with Biopharmaceutical Company
9.006-01NASDAQ.COMKamada Receives FDA Approval for New Laboratory
KMDA FAQ — answered by Alphio AI
Kamada Ltd is Israel based company, focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Kamada Ltd is a good buy right now due to its current price of 8.29, an RSI of 63.13 suggesting bullish momentum, and a strong gross margin of 40.91% in Q2 2026. The recent FDA approval for a new laboratory enhances its competitive position, while the company's reaffirmed revenue guidance of $200 million to $205 million for 2026 indicates confidence in future growth. However, a risk to consider is the recent earnings miss, with Q1 EPS reported at 0.07, falling short of expectations by 0.05.
1 analysts cover KMDA: 1 rate it Buy, 0 Hold and 0 Sell. The average price target is 14.00.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。